Companies / BOC Sciences / Figitumumab
BOC Sciences

Figitumumab | BOC Sciences

Figitumumab is a monoclonal antibody that targets the insulin-like growth factor type I receptor (IGF1R). Figitumumab binds to IGF1R, resulting in a reduction in receptor expression on tumor cells that express IGF1R and inhibition of tumor growth.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.